A Phase 3 interventional study of Autologous cardiac stem cells (JRM-001) in Hypoplastic Left Heart Syndrome and Single Ventricle, sponsored by Metcela Inc.. Recruiting at 4 sites in Japan. Open to participants aged 0 Years to 6 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Metcela Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of intracoronary injection of JRM-001 after reconstructive surgery in pediatric patients with functional single ventricle
67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.
This study's planned enrollment of 40 is above the median of 30 across 41 interventional studies indexed under Hypoplastic Left Heart Syndrome.
Browse Hypoplastic Left Heart Syndrome studies →Metcela Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic: Autologous cardiac stem cells (JRM-001)
3x 10\^5 cells/kg, single treatment
Change in ejection fraction (EF(%)) assessed by MRI from baseline
Time frame: Baseline, 6 and 12 months
Change in EF(%) assessed by echocardiograms from baseline
Time frame: Screening, Baseline, 3, 6 and 12 months
Change in EF(%) assessed by cardiac catheterization from baseline
Time frame: Baseline, 6 and 12 months
Change in Ea/Ees assessed by cardiac catheterization from baseline
Time frame: Baseline, 6 and 12 months
Change in Ventricular Stiffness assessed by cardiac catheterization from baseline
Time frame: Baseline, 6 and 12 months
Change in heart failure index from baseline
Time frame: Baseline, 3, 6 and 12 months
Change in Quality of Life (QOL) index from baseline
Time frame: Baseline, 6 and 12 months
Number of adverse events
Time frame: Up to 12 months
Plan to share: No
The record gives a start of Jun 2016, a primary completion of Dec 2028 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hypoplastic Left Heart Syndrome →
Metcela Inc.